Company Encyclopedia
View More
name
Hookipa Pharma
HOOK.US
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company’s immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc.
1.946 T
HOOK.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
E
BiotechnologyIndustry
Industry Ranking384/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-105.79%E
    • Profit Margin-784.01%E
    • Gross Margin-541.67%E
  • Growth ScoreE
    • Revenue YoY-82.54%E
    • Net Profit YoY-54.29%D
    • Total Assets YoY-58.01%E
    • Net Assets YoY-67.39%E
  • Cash ScoreE
    • Cash Flow Margin-12.75%D
    • OCF YoY-82.54%E
  • Operating ScoreE
    • Turnover0.09E
  • Debt ScoreC
    • Gearing Ratio44.36%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Hookipa Pharma Sells HBV and HIV Assets to Gilead

    HOOKIPA Pharma Inc. has completed the sale of its HB-400 and certain HB-500 program assets to Gilead Sciences, Inc. This transaction involves assets related to the clinical development of treatments for hepatitis B and HIV.

    Reuters·
    US
    GILD
    -1.90%
    US
    HOOK
    +3.06%
    Reuters·
    US
    GILD
    -1.90%
    US
    HOOK
    +3.06%

    Hookipa Pharma CEO Makes a Strategic Stock Move

    CEO Malte Peters of Hookipa Pharma sold 25,172 shares, earning $20,641. Spark's AI Analyst rates HOOK as Underperform due to severe financial issues, negative technical indicators, and poor valuation metrics. The company's asset liquidation strategy increases investment risk, making it speculative. Year-to-date, the stock has dropped 52.82%, with an average trading volume of 85,288 and a current market cap of $11.06M.

    Tip Ranks·
    US
    HOOK
    +3.06%
    Tip Ranks·
    US
    HOOK
    +3.06%

    Hookipa Pharma CEO Malte Peters Reports Disposal of Common Shares

    Malte Peters, CEO of Hookipa Pharma Inc., reported the disposal of common shares of the company. The full filing is available through the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice. The original content was published via EDGAR on October 09, 2025.

    Reuters·
    US
    HOOK
    +3.06%
    Reuters·
    US
    HOOK
    +3.06%

    Hookipa Pharma Inc. Conducted Special Stockholder Meeting to Vote on Key Proposals

    Hookipa Pharma Inc. held a special stockholder meeting on July 29, 2025, where stockholders approved the sale of certain assets to Gilead Sciences, Inc. and the company's liquidation and dissolution as per the Plan of Dissolution. The proposal to adjourn the meeting for additional proxy solicitation was also approved.

    Reuters·
    US
    HOOK
    +3.06%
    Reuters·
    US
    HOOK
    +3.06%

    EVP and CFO Mary Theresa Coelho Reports Disposal of Common Shares of Hookipa Pharma Inc

    Mary Theresa Coelho, EVP and CFO of Hookipa Pharma Inc., has reported the disposal of common shares of the company. The full filing is available through the provided link. This news brief was generated by Public Technologies and is for informational purposes only, not to be considered as financial, investment, or legal advice.

    Reuters·
    US
    HOOK
    +3.06%
    Reuters·
    US
    HOOK
    +3.06%
    © 2025 Longbridge｜Disclaimer